Hawkins Michelle, Robley Brian, Alem Farhang, Narayanan Aarthi, Larson Philip, Hull Jason, Hajduk Isabella, Wallach Michael
Camas Inc.
George Mason University.
Res Sq. 2025 Mar 19:rs.3.rs-5068132. doi: 10.21203/rs.3.rs-5068132/v1.
Despite the overall positive outcomes in hospitalization and mortality rates from the COVID-19 vaccines, COVID-19 infections remained prevalent around the world highlighting the need for alternative control strategies. Passive immunization with chicken IgY has long served as a feasible countermeasure, which gained further popularity in the research community during the recent pandemic. Here we demonstrate for the first time the scalability of anti-COVID-19 IgY production for effective distribution and potential use in large populations. Over 70,000 chickens were immunized against the SARS-CoV-2 S1 antigen to produce eggs containing anti-S1 IgY. The resulting egg yolk powder was formulated into commercially acceptable tablets for human consumption. QC and stability testing showed that the purified IgY and tablets maintained activity and stability for over a year. The resulting large batch of IgY tablets demonstrated equal immunoreactivity and virus neutralization potential against all leading COVID-19 strains. Our results demonstrate the feasibility of manufacturing egg yolk powder into edible tablets, and that can now be employed to block viral infectivity and transmission against all major COVID-19 strains affordably and effectively manner in both developed and developing countries.
尽管新冠疫苗在住院率和死亡率方面总体取得了积极成果，但新冠病毒感染在全球范围内仍然普遍存在，这凸显了采取替代控制策略的必要性。长期以来，用鸡IgY进行被动免疫一直是一种可行的对策，在最近的疫情期间，它在研究界更受欢迎。在此，我们首次展示了抗新冠病毒IgY生产的可扩展性，以便有效分发并有可能用于大量人群。超过70000只鸡接种了针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）S1抗原的疫苗，以生产含有抗S1 IgY的鸡蛋。将得到的蛋黄粉制成商业上可接受的供人类食用的片剂。质量控制和稳定性测试表明，纯化的IgY和片剂在一年多的时间里保持了活性和稳定性。由此生产的大量IgY片剂对所有主要的新冠病毒毒株都表现出同等的免疫反应性和病毒中和潜力。我们的结果证明了将蛋黄粉制成可食用片剂的可行性，并且现在可以在发达国家和发展中国家以经济有效的方式用于阻断针对所有主要新冠病毒毒株的病毒感染性和传播。
